Infinity PhII results a blow for PI3K in inflammation
This article was originally published in Scrip
Executive Summary
Infinity Pharmaceuticals has discontinued development of its oral PI3K inhibitor duvelisib in rheumatoid arthritis after the candidate failed in a Phase II trial.